[HTML][HTML] Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
MC Heinrich, RG Maki, CL Corless… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
MC Heinrich, RG Maki, CL Corless, CR Antonescu, A Harlow, D Griffith, A Town, A Mckinley…
Journal of clinical oncology, 2008•ncbi.nlm.nih.govPurpose Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived
growth factor receptor α (PDGFRA) kinases, which are imatinib targets. Sunitinib, which
targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with
GIST after they experience imatinib failure. We evaluated the impact of primary and
secondary kinase genotype on sunitinib activity.
growth factor receptor α (PDGFRA) kinases, which are imatinib targets. Sunitinib, which
targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with
GIST after they experience imatinib failure. We evaluated the impact of primary and
secondary kinase genotype on sunitinib activity.
Abstract
Purpose
Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor α (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with GIST after they experience imatinib failure. We evaluated the impact of primary and secondary kinase genotype on sunitinib activity.
ncbi.nlm.nih.gov